ARMP Delays Q4 2025 Results, Announces FDA QIDP for AP-SA02, Advances to Phase 3, Launches cGMP Facility
Armata Pharmaceuticals, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $7.80
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS